Cybin Inc. is pleased to announce that it has launched an overnight marketed public offering of common shares in the capital of the Company (the "Shares") at a price per Share and for aggregate gross proceeds to be determined in the context of the market.
The Barostim Neo System was granted U.S. Food and Drug Administration approval to treat symptoms of patients with advanced heart failure who are not candidates for treatment with other devices such as...